Connect Biopharma Holdings Limited
CNTB
$2.05
-$0.10-4.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.80% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.80% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.80% | -- | -- | -- | -- |
| SG&A Expenses | 6.26% | 21.26% | 48.27% | 48.27% | 9.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 87.87% | 87.87% | -- |
| Total Operating Expenses | 48.53% | -9.39% | -15.06% | -15.06% | -45.64% |
| Operating Income | -189.22% | 9.39% | 20.44% | 20.44% | 190.18% |
| Income Before Tax | -186.33% | -17.95% | 26.80% | 26.80% | 197.84% |
| Income Tax Expenses | 83.33% | 80.00% | 191.07% | 191.07% | -6.25% |
| Earnings from Continuing Operations | -186.88% | -18.16% | 26.41% | 26.41% | 197.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -186.88% | -18.16% | 26.41% | 26.41% | 197.44% |
| EBIT | -189.22% | 9.39% | 20.44% | 20.44% | 190.18% |
| EBITDA | -187.14% | 9.58% | 20.55% | 20.55% | 192.17% |
| EPS Basic | -186.39% | -17.62% | 26.68% | 26.68% | 197.18% |
| Normalized Basic EPS | -178.46% | -17.40% | 24.34% | 24.34% | 206.78% |
| EPS Diluted | -186.39% | -17.62% | 26.72% | 26.72% | 197.18% |
| Normalized Diluted EPS | -179.19% | -17.40% | 24.34% | 24.34% | 205.79% |
| Average Basic Shares Outstanding | 0.57% | 0.45% | 0.36% | 0.36% | 0.24% |
| Average Diluted Shares Outstanding | -0.38% | 0.45% | 0.36% | 0.36% | 1.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |